fluorodeoxyglucose f18 has been researched along with paclitaxel in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (25.00) | 29.6817 |
| 2010's | 40 (66.67) | 24.3611 |
| 2020's | 5 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Boyd, JH; Collins, BT; Dunleavy, T; Dunphy, FR; Fletcher, JW; Hollenbeak, C; Kim, H; Lowe, VJ; Martin, D; Stack, BC | 1 |
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Gillessen, S; Joerger, M; Klaeser, B; Kluckert, JT; Schmid, HP; Warzinek, T | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Baum, RP; Bonnet, R; Junker, K; Müller, KM; Schmücking, M | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Balkay, L; Galuska, L; Goda, K; Hernádi, Z; Krasznai, ZT; Major, T; Németh, E; Péli-Szabó, J; Szabó, G; Trón, L | 1 |
| Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M | 1 |
| Bares, R; Budach, W; Dittmann, H; Eschmann, SM; Friedel, G; Hehr, T; Langen, HJ; Paulsen, F; Reimold, M | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Ameshima, S; Demura, Y; Ishizaki, T; Mizuno, S; Morikawa, M; Okazawa, H | 1 |
| Balzarini, J; Berndsen, SC; Direcks, WG; Lammertsma, AA; Molthoff, CF; Peters, GJ; Proost, N; Spreeuwenberg, MD | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Dicker, DT; Dorsey, JF; Dowling, ML; El-Deiry, WS; Kao, GD; Mintz, A; Plastaras, JP; Tian, X | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP | 1 |
| Araki, O; Chida, M; Fukushima, Y; Honma, K; Inoue, T; Tamura, M; Tatewaki, M; Umezu, H | 1 |
| Fodor, Z; Galuska, L; Goda, K; Hernádi, Z; Krasznai, ZT; Mikecz, P; Szabó, G; Tóth, A | 1 |
| Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G | 1 |
| Bernardi, A; Castellucci, P; D'Errico Grigioni, A; De Iaco, P; Fanti, S; Lopci, E; Martoni, AA; Musto, A; Quercia, S; Ricci Maccarini, L; Rosati, M; Zamagni, C | 1 |
| Feng, R; Ma, L; Meng, X; Yu, JM; Yue, JB; Zhang, HQ | 1 |
| Cao, Q; Chen, X; Liu, S; Neamati, N; Niu, G; Shen, B; Sun, X; Yan, Y; Yang, M | 1 |
| Bergman, JJ; Boellaard, R; Bonenkamp, HJ; Bossuyt, PM; Busch, OR; Cuesta, MA; Hoekstra, OS; Hulshof, MC; Nieuwenhuijzen, GA; Omloo, JM; Plukker, JT; Pruim, J; Sloof, GW; Ten Kate, FJ; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ | 1 |
| Mason, DP | 1 |
| Behe, M; Braun, F; Grosu, AL; Milanović, D; Niedermann, G; Weber, W | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Anai, S; Harada, T; Ijichi, K; Koga, T; Kubo, N; Nakanishi, Y; Otsubo, K; Takayama, K; Yoneshima, Y | 1 |
| Drage, MG; Haddad, RI; Lichtman, AH; Shah, SM | 1 |
| Demura, Y; Kimura, H; Morikawa, M; Okazawa, H; Tsuchida, T; Umeda, Y | 1 |
| Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
| Gilhuijs, KG; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Valdés Olmos, RA; Vincent, AD; Vogel, WV; Vrancken Peeters, MJ; Wesseling, J | 1 |
| Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH | 1 |
| Crivellaro, C; Cuzzocrea, M; Dell'Anna, T; Dolci, C; Fruscio, R; Guerra, L; Messa, C; Milani, R; Signorelli, M; Sina, F | 1 |
| Chen, X; Eden, HS; Guo, J; Guo, N; Kiesewetter, DO; Lang, L; Li, Q; Niu, G; Xie, Q | 1 |
| Björkling, F; Erichsen, KD; Højgaard, L; Jensen, PB; Kjær, A; Madsen, J; Munk Jensen, M; Sehested, M | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Chan, WW; Choy, TS; Ho, PP; Khong, PL; Kwong, DL; Lam, KO; Lee, EY; Lee, VH; Leung, DK; Leung, TW | 1 |
| Cho, J; Choi, NC; Sharp, GC; Shusharina, N | 1 |
| Cortot, A; Hossein-Foucher, C; Olivier, A; Petyt, G; Scherpereel, A | 1 |
| Boughey, JC; Carey, LA; Carpenter, J; Connolly, RM; Davidson, NE; Fetting, JH; Gabrielson, E; Goetz, MP; Jacobs, LK; Jeter, SC; Khouri, N; Leal, JP; Mhlanga, J; Miller, RS; O, JH; Powers, P; Sideras, K; Stearns, V; Storniolo, AM; Wahl, RL; Walsh, B; Watkins, S; Wolff, AC; Zhang, Z; Zhou, XC; Zorzi, J | 1 |
| Abu-Khalaf, MM; Azodi, M; Baumgart, MA; Chen, N; Deshpande, H; Digiovanna, MP; Doddamane, I; Gettinger, SN; Harris, LN; Hatzis, C; Hou, S; Lezon-Geyda, K; Schwartz, PE; Sullivan, C; Tuck, DP; Zelterman, D | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Chino, Y; Fujita, Y; Kiyono, Y; Kurokawa, T; Okazawa, H; Tsujikawa, T; Yamamoto, M; Yoshida, Y | 1 |
| Boellaard, R; de Jong, EE; Dingemans, AC; Groen, HJ; Hoekstra, OS; Lambin, P; Leijenaar, RT; Smit, EF; Troost, EG; van der Noort, V; van Elmpt, W | 1 |
| Amiri-Kordestani, L; Balasubramaniam, S; Bates, SE; Bryla, C; Burotto, M; Choyke, P; Davarpanah, N; Figg, WD; Fojo, T; Gonzalez, EM; Liewehr, DJ; Lindenberg, M; O'Sullivan, CC; Patronas, N; Peer, CJ; Steinberg, SM | 1 |
| Elkhuizen, PH; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Stokkel, MP; Teixeira, SC; Valdés Olmos, RA; van der Noort, V; Vrancken Peeters, MT | 1 |
| Chen, Y; Fu, S; Sun, X; Wu, J; Xu, S; Yang, B; Yang, L; You, H; Yu, Y; Zhang, Y | 1 |
| Bi, N; Cease, KB; Frey, KA; Gross, M; Hassan, KA; Hayman, J; Kalemkerian, GP; Kong, FM; Lawrence, TS; Matuszak, M; Orringer, M; Ramnath, N; Ritter, T; Schipper, M; Ten Haken, RK; Wang, W | 1 |
| Chen, Q; Chen, Y; Dong, Y; Liu, H; Song, F; Tian, M; Wang, L; Wu, S; Xu, C; Zhang, H; Zhang, K; Zhou, M; Zhu, Y | 1 |
| Hu, P; Jin, C; Ma, B; Pan, Q; Wei, Z; Zhang, BN | 1 |
| Akashi, K; Ariyama, H; Baba, E; Doi, G; Harimoto, N; Itoh, S; Kohashi, K; Kusaba, H; Maehara, Y; Nio, K; Oda, Y; Odawara, J; Shimoda, S; Takayoshi, K; Tsuchihashi, K; Tsuruta, N; Yoshihiro, T | 1 |
| Belloli, S; Bogni, A; Bombardieri, E; Daidone, MG; Moresco, RM; Pascali, C; Presotto, L; Raccagni, I; Russo, G; Stefano, A; Tortoreto, M; Valtorta, S; Zaffaroni, N | 1 |
| Bennink, RJ; Bijlsma, MF; Creemers, A; Ebbing, EA; Hulshof, MCCM; Jibodh, RA; Krishnadath, KK; Medema, JP; Meijer, SL; Punt, CJA; Steins, A; van Delden, OM; van der Zalm, AP; van Laarhoven, HWM; Waasdorp, C | 1 |
| Abgral, R; Amrane, K; Metges, JP; Querellou, S; Schick, U | 1 |
| Bastien, C; Campitiello, M; Gehin, W; Hennequin, L; Jaud, C; Longo, R; Plastino, F; Rozzi, A | 1 |
| Aoyama, M; Bando, Y; Inoue, S; Kawakita, N; Kondo, K; Otani, T; Takizawa, H; Tangoku, A; Tsuboi, M; Uehara, H | 1 |
| Bowen, SR; Gates, EDH; Hippe, DS; Vesselle, HJ; Zeng, J | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
3 review(s) available for fluorodeoxyglucose f18 and paclitaxel
| Article | Year |
|---|---|
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
18 trial(s) available for fluorodeoxyglucose f18 and paclitaxel
| Article | Year |
|---|---|
Surveillance for recurrent head and neck cancer using positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Tomography, Emission-Computed | 2000 |
[Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; ROC Curve; Treatment Outcome | 2011 |
Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2013 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Preoperative Period; Receptor, ErbB-2; Safety; Time Factors; Treatment Outcome; Young Adult | 2015 |
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Netherlands; Nitroglycerin; Paclitaxel; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Vasodilator Agents | 2017 |
ANG1005 for breast cancer brain metastases: correlation between
Topics: Adult; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Peptides; Positron-Emission Tomography; Treatment Outcome | 2016 |
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2017 |
Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunity; Lung Neoplasms; Paclitaxel; Pneumonia; Positron Emission Tomography Computed Tomography; Radiation Pneumonitis; Radiation Tolerance | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
40 other study(ies) available for fluorodeoxyglucose f18 and paclitaxel
| Article | Year |
|---|---|
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms; Penis; Remission Induction; Survival Analysis; Tomography, Emission-Computed | 2004 |
Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Kinetics; Paclitaxel; Protein Binding; Radioactive Tracers; Radiopharmaceuticals; Technetium Tc 99m Sestamibi | 2006 |
Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy; Sensitivity and Specificity; Treatment Outcome | 2006 |
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis | 2007 |
FDG positron emission tomography imaging of drug-induced pneumonitis.
Topics: Aged; Anxiety Disorders; Brain Neoplasms; Breast Neoplasms; Dibenzothiazepines; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonia; Positron-Emission Tomography; Quetiapine Fumarate; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Doxorubicin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Paclitaxel; Thymidine; Thymidine Kinase | 2008 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Fluorodeoxyglucose F18; Glioblastoma; Humans; Luminescent Measurements; Mice; Mice, Nude; Paclitaxel; Positron-Emission Tomography; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymphatic Irradiation; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy Dosage; Time Factors | 2011 |
Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2010 |
Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Female; Fluorodeoxyglucose F18; Glucose; Humans; Ovarian Neoplasms; Paclitaxel; Protein Binding; Rhodamine 123; Technetium Tc 99m Sestamibi; Tumor Cells, Cultured | 2010 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome | 2010 |
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
Topics: Adult; Aged; Carboplatin; Chemotherapy, Adjuvant; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
[Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2010 |
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Integrin alphaVbeta3; Mammary Neoplasms, Experimental; Mice; Oligopeptides; Paclitaxel; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2011 |
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Mice; Mice, Nude; Paclitaxel; Positron-Emission Tomography; Tumor Burden; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Staging; Neoplasms, Muscle Tissue; Paclitaxel; Positron-Emission Tomography; Radiography; Thoracic Vertebrae; Treatment Outcome | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Diagnosis, Differential; Drug Administration Schedule; Fatal Outcome; Fluorodeoxyglucose F18; Fluorouracil; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Immunohistochemistry; Laryngoscopy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Papillomavirus Infections; Positron-Emission Tomography; Pulmonary Artery; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Thrombophilia; Tomography, X-Ray Computed; Vascular Neoplasms | 2012 |
Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Trastuzumab | 2013 |
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
(18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors | 2014 |
Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorodeoxyglucose F18; Heterografts; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2016 |
Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Topics: Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Conformal; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Burden | 2014 |
Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Prognosis; Tumor Burden | 2016 |
PET/CT with
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Trastuzumab; Young Adult | 2017 |
In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Chemoradiotherapy; Drug Carriers; Drug Compounding; Female; Fluorodeoxyglucose F18; HeLa Cells; Humans; Immunohistochemistry; Ki-67 Antigen; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Polyesters; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Technology, Pharmaceutical; Time Factors; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2017 |
PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Fluorodeoxyglucose F18; Humans; Mammary Neoplasms, Experimental; Medicine, Chinese Traditional; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Positron-Emission Tomography | 2018 |
Effects of WD‑3 on tumor growth and the expression of integrin αvβ3 and ERK1/2 in mice bearing human gastric cancer using the 18F‑RGD PET/CT imaging system.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Integrin alphaVbeta3; MAP Kinase Signaling System; Medicine, Chinese Traditional; Mice; Paclitaxel; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report.
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Cytotoxins; Etoposide; Female; Fluorodeoxyglucose F18; Hemangioma; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Middle Aged; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Splenectomy; Splenic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2018 |
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Mice, Nude; Mice, SCID; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Thymidine; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2018 |
Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Esophageal Mucosa; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Primary Cell Culture; Progression-Free Survival; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab | 2020 |
Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report.
Topics: Carboplatin; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Cetuximab; Drug Therapy, Combination; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Middle Aged; Nasal Cavity; Nose Neoplasms; Paclitaxel; Palliative Care; Positron-Emission Tomography; Rare Diseases | 2020 |
Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Mice; Paclitaxel; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinolines; Thyroid Carcinoma, Anaplastic; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |